Based on the Anixa Biosciences Inc stock forecast from 2 analysts, the average analyst target price for Anixa Biosciences Inc is USD 7.75 over the next 12 months. Anixa Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Anixa Biosciences Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Anixa Biosciences Inc’s stock price was USD 2.66. Anixa Biosciences Inc’s stock price has changed by -5.34% over the past week, +3.10% over the past month and -11.33% over the last year.
No recent analyst target price found for Anixa Biosciences Inc
No recent average analyst rating found for Anixa Biosciences Inc
Company Overview Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Read Less
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T c...Read More
Frequently Asked Questions About Anixa Biosciences Inc (ANIX) Stock
Based on ratings from 2 analysts Anixa Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANIX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ANIX is USD 7.75 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on ANIX's stock to indicate if its overvalued.
The last closing price of ANIX's stock was USD 2.66.
The most recent market capitalization for ANIX is USD 0.08B.
Based on targets from 2 analysts, the average taret price for ANIX is projected at USD 7.75 over the next 12 months.
This means that ANIX's stock price may go up by +191.35% over the next 12 months.
We can't find any ETFs which contains Anixa Biosciences Inc's stock.
As per our most recent records Anixa Biosciences Inc has 5 Employees.
Anixa Biosciences Inc's registered address is 3150 Almaden Expressway, San Jose, CA, United States, 95118.
You can get more information about it from Anixa Biosciences Inc's website at https://www.anixa.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Anixa Biosciences Inc (ANIX) Stock
Based on ratings from 2 analysts Anixa Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANIX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ANIX is USD 7.75 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on ANIX's stock to indicate if its overvalued.
The last closing price of ANIX's stock was USD 2.66.
The most recent market capitalization for ANIX is USD 0.08B.
Based on targets from 2 analysts, the average taret price for ANIX is projected at USD 7.75 over the next 12 months.
This means that ANIX's stock price may go up by +191.35% over the next 12 months.
We can't find any ETFs which contains Anixa Biosciences Inc's stock.
As per our most recent records Anixa Biosciences Inc has 5 Employees.
Anixa Biosciences Inc's registered address is 3150 Almaden Expressway, San Jose, CA, United States, 95118.
You can get more information about it from Anixa Biosciences Inc's website at https://www.anixa.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ANIX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
